Previous Article | Next Article 
Journal of Clinical Microbiology, March 1998, p. 764-767, Vol. 36, No. 3
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Method for Reduction of Inhibition in a
Mycobacterium tuberculosis-Specific Ligase Chain Reaction
DNA Amplification Assay
Gregor W.
Leckie,
Dwight D.
Erickson,
Qizhi
He,
Ingrid E.
Facey,
Bor-Chian
Lin,
Jianli
Cao, and
Folim G.
Halaka*
Probe Diagnostics, Abbott Laboratories,
Abbott Park, Illinois 60064-3500
Received 28 August 1997/Returned for modification 6 October
1997/Accepted 5 December 1997
 |
ABSTRACT |
The present study describes the identification of inhibitors of a
Mycobacterium tuberculosis-specific gap ligase chain
reaction (LCR) DNA amplification assay as well as a method for their
removal. A major contributor to inhibition was deduced to be a calcium phosphate precipitate, CaHPO4. The precipitate forms during
N-acetyl-L-cysteine-sodium hydroxide
(NALC-NaOH) decontamination, digestion, and concentration of
respiratory specimens. The solubility product of
CaHPO4 precipitate at pH 7.8, the pH at which gap LCR is
optimized, indicates that the precipitate releases an amount of
phosphate ions sufficient to inhibit amplification. A method for
removal of the precipitate was identified. The precipitate is
dissociated by exposing it to a mildly acidic (pH 4.1) buffer during
the first of two centrifugation steps; the inhibitory phosphate ions
are removed by the centrifugation steps. When 100 NALC-NaOH
respiratory sediments were tested by gap LCR, none of the sediments
were inhibitory when the acidic buffer was used while 24 samples were
inhibitory when TE buffer, pH 7.8, was used. In another study, when the
acidic buffer wash was applied to 1,440 NALC-NaOH respiratory
sediments, only 10 sediments were found to be inhibitory. None of
the inhibited sediments were culture positive for M. tuberculosis. This work demonstrates that when
inhibition mechanisms are identified, relatively simple protocols can
be used to obtain low inhibition rates and to allow the use of
larger volume equivalents in amplification reactions.
 |
INTRODUCTION |
Many groups have developed
Mycobacterium tuberculosis-specific nucleic acid
amplification assays for rapid detection of active tuberculosis
(16, 22). The utility of these assays, however, has been
limited by specimen-associated inhibitors. Inhibitors reduce the
activity of the enzyme(s) responsible for nucleic acid amplification,
which can result in false-negative assay results (6, 16,
22). Inhibition rates varying from 3 to 52% have been reported
when M. tuberculosis-specific PCR assays have been used to
test respiratory specimens decontaminated, digested, and concentrated
by N-acetyl-L-cysteine-sodium hydroxide
(NALC-NaOH) (1, 12, 20, 21, 24), NaOH (2, 14, 15,
25), sputolysin-NaOH (26), and sodium lauryl
sulfate-NaOH (9) protocols. In these studies, lower
inhibition rates (5% or less) were obtained when relatively small
volume equivalents (
25 µl) of NALC respiratory sediment were tested
per amplification reaction or when the sediments underwent relatively
complex specimen processing protocols prior to amplification.
Ligase chain reaction (LCR) is a DNA amplification method which uses
thermostable DNA ligase for the detection of infectious agents, as well
as point mutations associated with cancer, and genetic disease (5,
8). A more sensitive version of LCR, called gap LCR, requires
thermostable DNA polymerase in addition to thermostable DNA ligase
(4, 8). Gap LCR assays have been developed on the automated
LCx system for the specific detection of Chlamydia
trachomatis, Neisseria gonorrhoeae, and
Mycobacterium tuberculosis (7, 10, 11, 13, 17).
The purpose of this study was to identify the major inhibitor(s) of gap
LCR in NALC-NaOH respiratory sediments and to develop simple methods to
alleviate inhibition, so that a relatively large volume equivalent (100 µl) of sediment could be tested per assay. The present study
demonstrates that phosphate ions are potent inhibitors of gap LCR
amplification. It also suggests that the NALC-NaOH decontamination,
digestion, and concentration process, in which phosphate buffer is
added, produces a calcium phosphate precipitate which acts as a source
of inhibitory phosphate ions. Finally, methods for alleviation of the
inhibitory effects of these substances are presented.
 |
MATERIALS AND METHODS |
Specimen collection, transport, and storage.
Respiratory
specimens were decontaminated, digested, and concentrated by the
NALC-NaOH protocol (18). Following microscopy for detection
of acid-fast bacteria and the initiation of liquid and solid cultures,
the remainder of each NALC-NaOH respiratory sediment was transported to
Abbott Laboratories and stored at 2 to 8 or
20°C.
Preparation of calcium phosphate precipitate.
Ten
milliliters of water, 5 or 10 mM calcium chloride solutions were
incubated individually with 10 ml of 3% NaOH for 15 min at room
temperature, after which 30 ml of 67 mM phosphate buffer (pH 6.8) was
added. After the addition of the phosphate buffer, the tubes were
centrifuged at 2,000 × g for 30 min. The supernatants were removed, and each pellet was resuspended in 5 ml of 67 mM phosphate buffer, pH 6.8.
LCR.
Specimens (either phosphate buffer [pH 6.8], calcium
phosphate precipitate, or NALC-NaOH respiratory sediments) were
vortexed for 2 to 5 s, after which 500-µl aliquots were pipetted
into 1.7-ml screw-cap tubes which contained 50 mg of 150- to 212-µm
acid-washed glass beads and 900 µl of buffer. The buffer used was
either 10 mM Tris-HCl (pH 7.8)-1 mM EDTA (TE) buffer, 0.5 M potassium
acetate buffer (pH 4.1), or 1.0 M potassium acetate buffer (pH 4.1).
After the specimens were added, the tubes were recapped and vortexed for 2 to 5 s before being centrifuged at 1,500 × g for 10 min in an aerosol-contained clinical centrifuge.
The supernatant was removed from every tube, and each pellet was
resuspended in 1.0 ml of resuspension buffer [30 mM
N-(2-hydroxyethyl)
piperazine-N-(3-propanesulfonic acid) (EPPS) (pH 7.8), 75 mM
magnesium chloride, 0.001% acetylated bovine serum albumin, 0.0003%
amaranth dye, and 1% sodium azide]. The tubes were recapped, vortexed
for 2 to 5 s, and centrifuged (1,500 × g for 10 min). The supernatants were removed, and each pellet was resuspended in
0.5 ml of resuspension buffer. The recapped tubes were vortexed for 2 to 5 s and incubated at 95°C for 20 min in an LCx covered dry
bath. After being heated, the specimens were allowed to cool to room
temperature and then were sonicated for a defined time (approximately
10 min) in an LCx Lysor. Sonication was performed to increase the
efficiency with which mycobacteria were lysed. After sonication, the
specimen tubes were microfuged for 2 min before gap LCR amplification
was initiated.
One hundred microliters of processed specimens was added to an
amplification vial which contained 100 µl of prealiquoted
amplification mixture. After the specimens were added, each gap LCR
assay mixture contained 18,000 U of recombinant Thermus
thermophilus thermostable DNA ligase, 2 U of native Thermus
flavus thermostable DNA polymerase, 5 µM NAD, 37.5 mM magnesium
chloride, 1 mM spermidine, 0.001% acetylated bovine serum albumin, 1.0 µM dATP, 1.0 µM dCTP, 10 mM potassium as either potassium chloride
or potassium hydroxide, 40 mM EPPS buffer (pH 7.8), 0.00015% amaranth
dye, 0.6% sodium azide, and 1012 of each of the four
probes which constitute the LCR probe set. The probe set was designed
to detect nucleotides 347 to 390 of the single-copy chromosomal gene
which encodes protein antigen b of M. tuberculosis
(3). The PAB gene appears to be specific to the four
subspecies of the M. tuberculosis complex (11, 14, 23,
26). Gap LCR assay mixtures were thermocycled (37 cycles of
94°C for 1 s, 64°C for 1 s, and 69°C for 40 s) in
an LCx thermal cycler. Two calibrators (25 M. tuberculosis
DNA genomes in 1 µg of salmon testes DNA per gap LCR amplification
mixture) and two negative controls (1 µg of salmon testes DNA per gap
LCR amplification reaction mixture) were subjected to thermocycling
along with each batch of 20 processed specimens. After thermocycling,
double-hapten-labeled amplification product, if produced, was detected
by microparticle enzyme immunoassay on an LCx analyzer, a 24-position
automated batch analyzer, with the following run order: two negative
controls, two calibrators, 20 specimens. Detectable fluorescence was
expressed as counts per second per second. The assay cutoff was 0.3 times the mean fluorescence rate of the two calibrators. Specimens were considered gap LCR positive if their sample-to-cutoff (S/CO) ratios were
1.0. After detection, the LCx analyzer chemically inactivated the amplification product (17).
Detection of inhibitors.
Each specimen processed for gap LCR
amplification was amplified in the presence of 25 M. tuberculosis DNA genomes, which were added as a 10-µl spike-in.
Specimens were considered inhibitory if their S/CO ratio was <1.0.
 |
RESULTS |
Phosphate buffer inhibition.
Phosphate buffer (67 mM; pH 6.8)
was diluted so that the final concentrations in gap LCR mixtures were
2.16, 1.08, 0.54, and 0.27 mM. Each dilution, as well as a water
control, was tested in triplicate for the presence of inhibition. Table
1 shows that two of three gap LCR assays
were inhibited when each mixture contained 2.16 mM phosphate buffer, pH
6.8. No inhibition was observed when the concentration of phosphate
buffer, pH 6.8, in gap LCR amplification mixtures was reduced to 1.08 mM. Consequently, the inhibitory threshold of gap LCR amplification for
phosphate buffer, pH 6.8, lies between 1.08 mM and 2.16 mM. A
double-centrifugation protocol was instituted to assure that phosphate
buffer was diluted consistently below the inhibitory threshold for gap
LCR amplification.
Calcium phosphate precipitate formation and removal of its
inhibitory effect by using potassium acetate buffer (pH 4.1).
Visible precipitate was formed when mock specimens, consisting of
either 5 or 10 mM CaCl2, were subjected to conditions
similar to those found under NALC-NaOH decontamination, digestion, and concentration. No precipitate was formed when water was used as the
mock specimen. Even though the precipitate was not chemically identified, it was believed to be calcium phosphate. The calcium phosphate precipitate was inhibitory to gap LCR amplification when the
first centrifugation was performed with 10 mM TE buffer, pH 7.8 (Table
2). By contrast, the inhibitory effect of
the calcium phosphate precipitate was partially removed when the first
centrifugation was performed with 0.5 M potassium acetate buffer, pH
4.1, and completely removed when 1.0 M potassium acetate buffer, pH
4.1, was used in the first centrifugation.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Inhibitory effect of calcium phosphate precipitate on
gap LCR amplification and removal of inhibition by potassium
acetate buffer, pH 4.1
|
|
Comparison of TE buffer (pH 7.8) with potassium acetate buffer (pH
4.1) for removal of inhibition.
Separate aliquots from 100 NALC-NaOH respiratory sediments were processed with either 10 mM TE
buffer (pH 7.8) or 1.0 M potassium acetate buffer (pH 4.1). Inhibition
testing determined that 24 of the TE-processed specimens inhibited gap
LCR amplification (Fig. 1). By contrast,
none of the same NALC-NaOH respiratory sediments were inhibitory to gap
LCR amplification when processed with 1.0 M potassium acetate buffer,
pH 4.1. Figure 1 also shows that some sediments produced considerably
higher S/CO ratios than others. This is likely the result of these
sediments containing endogenous M. tuberculosis DNA in
addition to the M. tuberculosis DNA added to test for
inhibition.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 1.
Frequency distribution of a comparison between TE, pH
7.8, and 1.0 M potassium acetate buffer, pH 4.1, for the removal of
inhibition. A portion of each NALC-NaOH respiratory sediment was
processed with either TE, pH 7.8, or 1.0 M potassium acetate buffer, pH
4.1, before being tested by gap LCR amplification in the presence of 25 purified M. tuberculosis DNA genomes. A NALC-NaOH
respiratory sediment was considered inhibitory if its gap LCR
amplification produced an S/CO ratio of <1.0.
|
|
Effectiveness of 1.0 M potassium acetate buffer (pH 4.1) for
removing inhibition from NALC-NaOH respiratory sediments.
A
total of 1,440 NALC-NaOH respiratory sediments were processed with 1.0 M potassium acetate buffer, pH 4.1, and then each specimen was tested
twice by gap LCR. The first gap LCR assay was performed to determine if
the specimen contained endogenous M. tuberculosis DNA, while
the second was done to determine if the sample inhibited gap LCR. Of
the 1,440 specimens, 197 contained endogenous M. tuberculosis DNA. Gap LCR detected 116 of 128 specimens that were
culture positive for M. tuberculosis (61 of 62 microscopy-positive and 55 of 66 microscopy-negative specimens were gap
LCR positive). Ten of the 1,440 specimens inhibited gap LCR. However,
none of the inhibitory specimens were culture positive for M. tuberculosis.
 |
DISCUSSION |
The development of relatively simple specimen preparation
protocols that reduce the inhibitory potential of NALC-NaOH respiratory sediments would increase the utility of DNA amplification reactions for
the detection of M. tuberculosis. When inhibition is
substantially reduced, assay sensitivity can be increased by
permitting greater volume equivalents of NALC-NaOH respiratory sediment
to be tested per amplification reaction. Fulfillment of this goal
requires that the most important inhibitors be identified and
effectively removed.
Phosphate ions at concentrations as low as 1 to 2 mM were found to
inhibit gap LCR amplification. This is an issue because 67 mM phosphate
buffer, pH 6.8, is added to respiratory specimens during the NALC-NaOH
decontamination, digestion, and concentration process. A
double-centrifugation protocol was therefore instituted to reduce the
concentration of phosphate ions to below 1.0 mM, when 100-µl
equivalents of NALC-NaOH sediment were tested per gap LCR amplification
assay. Despite the use of the double-centrifugation protocol, a
substantial proportion of NALC-NaOH respiratory sediments inhibited gap
LCR amplification. An explanation for the remaining inhibition is the
fact that some inhibitors are not removed by the centrifugation steps
but instead centrifuge down with the M. tuberculosis
bacilli.
One such substance was deduced to be calcium phosphate precipitate,
Ca3(PO4)2. This highly insoluble
precipitate (solubility product, 0.06 mM) (19) formed when
calcium ion-containing specimens were treated with the alkaline
NALC-NaOH solution, followed by the addition of phosphate buffer. The
precipitate would centrifuge down with M. tuberculosis
bacilli and would not be removed even when two centrifugation steps
were performed. If the precipitate was subjected to a near-neutral pH,
such as pH 7.8, which is found in gap LCR amplification assays, it
would convert to a more soluble (solubility product, 1.84 mM) type of
precipitate (CaHPO4) (19). The higher
concentration of phosphate ions would inhibit gap LCR amplification. If
a calcium phosphate precipitate was the culprit, it follows that
inhibition could be reduced if the precipitate was dissociated by
exposure to acidic conditions and then had its ionic constituents
removed by double centrifugation. This conclusion was supported by the
observations that calcium phosphate precipitate was formed in a process
similar to NALC-NaOH decontamination, digestion, and concentration;
that this precipitate inhibited gap LCR when sediments were processed
with TE buffer, pH 7.8; and that inhibition was reduced significantly
when mildly acidic buffer, pH 4.1, was used in place of TE buffer.
The utility of the double-centrifugation protocol, in which the
first centrifugation was performed in the presence of a mildly acidic
buffer, was demonstrated when 1,440 NALC-NaOH respiratory sediments were processed and tested for the presence of inhibitors, as
well as for endogenous M. tuberculosis DNA. Only 10 sediments were found to be inhibitory to gap LCR. In addition, none of
128 specimens that were culture positive for M. tuberculosis
showed inhibition. Gap LCR results indicated that 197 sediments
contained endogenous M. tuberculosis DNA, and they were not
included in the inhibition rate calculations. This is due to our
definition of inhibition, which is based on a S/CO ratio of
<1.0 when 25 M. tuberculosis genomes are added to
negative specimens. Sediments containing endogenous M. tuberculosis DNA will produce higher gap LCR signals, giving rise
to S/CO ratios of >1, even though partial inhibition may be present.
The gap LCR inhibition rate was thus calculated to be 0.8% (10 of
1,243).
The inhibition rates achieved here are substantially lower than those
reported by other workers who also tested a relatively large volume
equivalent of NALC-NaOH respiratory sediment per amplification assay,
following centrifugation to remove inhibitors. Nolte et al.
(20) observed an inhibition rate of 13.6% when using a PCR
internal control, after processing NALC-NaOH respiratory sediments with
a single centrifugation step and then testing 50- to 100-µl
equivalents of NALC-NaOH respiratory sediment per PCR amplification. By
contrast, Clarridge et al. (12) centrifuged each specimen
twice before testing 166-µl equivalents of NALC-NaOH respiratory
sediment per PCR assay; they observed that 14.3% (4 of 28 sputa or
bronchial washes) of PCR-negative specimens which were culture positive
for M. tuberculosis contained inhibitors.
Low inhibition rates have been achieved by other workers by testing
small volume equivalents (
25 µl) of respiratory sediment per
amplification reaction after performing a simple specimen preparation
protocol or by testing >25-µl equivalents per amplification reaction
after performing relatively complicated, multistep specimen preparation
protocols (1, 2, 9, 21, 24, 26). Both of these strategies
have disadvantages. Testing small volume equivalents of respiratory
sediment per amplification reaction reduces sensitivity compared
to that of BACTEC liquid culture, which uses 500 µl of respiratory sediment per culture. By contrast, the more complicated the
specimen preparation method, the more it is prone to
cross-contamination and loss of analyte (25).
This work demonstrates the value of identifying the most potent
inhibitors of nucleic acid amplification reactions. It permits simple
protocols to be designed which effectively remove the most troublesome
inhibitors and also promotes increased sensitivity by permitting
relatively large volume equivalents of specimen to be tested per
amplification reaction.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Abbott
Laboratories, Department 9NF, Building AP20, 100 Abbott Park Rd.,
Abbott Park, IL 60064-3500. Phone: (847) 938-9499. Fax: (847) 938-8777. E-mail: Folim.Halaka{at}ADDSSW.ABBOTT.COM.
 |
REFERENCES |
| 1.
|
Amicosante, M.,
L. Richeldi,
G. Trenti,
G. Paone,
M. Campa,
A. Bisetti, and C. Saltini.
1995.
Inactivation of polymerase inhibitors for Mycobacterium tuberculosis DNA amplification in sputum by using capture resin.
J. Clin. Microbiol.
33:629-630[Abstract].
|
| 2.
|
Andersen, A. B.,
S. Thybo,
P. Godfrey-Faussett, and N. G. Stoker.
1993.
Polymerase chain reaction for detection of Mycobacterium tuberculosis in sputum.
Eur. J. Clin. Microbiol. Infect. Dis.
12:922-927[Medline].
|
| 3.
|
Andersen, Å. B., and E. B. Hansen.
1989.
Structure and mapping of antigenic domains of protein antigen b, a 38,000-molecular-weight protein of Mycobacterium tuberculosis.
Infect. Immun.
57:2481-2488[Abstract/Free Full Text].
|
| 4.
|
Backman, K.
1992.
Diagnostic technology for the 1990s and beyond.
Clin. Chem.
38:457-458[Free Full Text].
|
| 5.
|
Barany, F.
1991.
Ligase chain reaction in a PCR world.
PCR Methods Applic.
5:5-16.
|
| 6.
|
Betsch, D. F.
1995.
Nucleic acid amplification-based diagnostics: barriers to commercialization.
Med. Rev. Diagn. Ind.
17:22-28.
|
| 7.
|
Birkenmeyer, L., and A. S. Armstrong.
1992.
Preliminary evaluation of the ligase chain reaction for specific detection of Neisseria gonorrhoeae.
J. Clin. Microbiol.
30:3089-3094[Abstract/Free Full Text].
|
| 8.
|
Birkenmeyer, L. G., and I. K. Mushahwar.
1991.
DNA probe amplification methods.
J. Virol. Methods
35:117-126[Medline].
|
| 9.
|
Brisson-Noel, A.,
C. Aznar,
C. Chureau,
S. Nguyen,
C. Pierre,
M. Bartoli,
R. Bonette,
G. Pialoux,
B. Gicquel, and G. Garrigue.
1991.
Diagnosis of tuberculosis by DNA amplification in clinical practice evaluation.
Lancet
338:364-366[Medline].
|
| 10.
|
Burczak, J. D.,
S. F. Ching,
H. Y. Hu, and H. Lee.
1995.
Ligase chain reaction for the detection of infectious agents, p. 315-327.
In
D. Wiedbrauk, and D. H. Farkas (ed.), Molecular methods for virus detection. Academic Press, Inc., New York, N.Y.
|
| 11.
|
Cao, J.,
A. Davis,
D. Erickson,
I. Facey,
F. Halaka,
Q. He,
H. Hu,
D. Kawa,
B.-C. Lin,
G. Winter, and G. Leckie.
1996.
Direct detection of Mycobacterium tuberculosis by the LCxR Mycobacterium tuberculosis assay, abstr. U-10.
In
Abstracts of the 96th General Meeting of the American Society for Microbiology 1996. American Society for Microbiology, Washington, D.C.
|
| 12.
|
Clarridge, J. E.,
R. M. Shawar,
T. M. Shinnick, and R. B. Plikaytis.
1993.
Large-scale use of polymerase chain reaction for detection of Mycobacterium tuberculosis in a routine mycobacteriology laboratory.
J. Clin. Microbiol.
31:2049-2056[Abstract/Free Full Text].
|
| 13.
|
Dille, B. J.,
C. C. Butzen, and L. G. Birkenmeyer.
1992.
Amplification of Chlamydia trachomatis DNA by ligase chain reaction.
J. Clin. Microbiol.
31:729-731[Abstract/Free Full Text].
|
| 14.
|
Forbes, B. A., and K. E. S. Hicks.
1993.
Direct detection of Mycobacterium tuberculosis in respiratory specimens using a polymerase chain reaction.
J. Clin. Microbiol.
31:1688-1694[Abstract/Free Full Text].
|
| 15.
|
Forbes, B. A., and K. E. Hicks.
1996.
Substances interfering with direct detection of Mycobacterium tuberculosis in clinical specimens by PCR: effects of bovine serum albumin.
J. Clin. Microbiol.
34:2125-2128[Abstract].
|
| 16.
|
Forbes, B. A.
1997.
Critical assessment of gene amplification approaches on the diagnosis of tuberculosis.
Immunol. Investig.
26:105-116[Medline].
|
| 17.
|
Hu, H. Y.,
J. D. Burczak,
G. W. Leckie,
K. A. Ray,
S. Muldoon, and H. H. Lee.
1996.
Analytic performance and contamination control methods of a ligase chain reaction DNA amplification assay for detection of Chlamydia trachomatis in urogenital specimens.
Diagn. Microbiol. Infect. Dis.
24:71-76[Medline].
|
| 18.
|
Kent, P. T., and G. P. Kubica.
1985.
Public health mycobacteriology. A guide for the level III laboratory.
Centers for Disease Control, Atlanta, Ga.
|
| 19.
|
Lide, D. R. (ed.).
1994.
CRC handbook of chemistry and physics, 1993-1994, p. 4-49.
CRC Press Inc., Boca Raton, Fla.
|
| 20.
|
Nolte, F. S.,
B. Metchock,
J. E. McGowan,
A. Edwards,
O. Okwumabua,
C. Thurmond,
P. S. Mitchell,
B. Plikaytis, and T. Shinnick.
1993.
Direct detection of Mycobacterium tuberculosis in sputum by polymerase chain reaction and DNA hybridization.
J. Clin. Microbiol.
31:1777-1782[Abstract/Free Full Text].
|
| 21.
|
Noordhoek, G. T.,
J. A. Kaan,
S. Mulder,
H. Wilke, and A. H. J. Kolk.
1995.
Routine application of the polymerase chain reaction for detection of Mycobacterium tuberculosis in clinical samples.
J. Clin. Pathol.
48:810-814[Abstract/Free Full Text].
|
| 22.
|
Pfyffer, G. E.
1994.
Amplification techniques: hope or illusion in the direct detection of tuberculosis?
Med. Microbiol. Lett.
3:335-347.
|
| 23.
|
Sjobring, U.,
M. Mecklenburg,
A. B. Andersen, and H. Miorner.
1990.
Polymerase chain reaction for detection of Mycobacterium tuberculosis.
J. Clin. Microbiol.
28:2200-2204[Abstract/Free Full Text].
|
| 24.
|
Soini, H.,
M. Skurnik,
K. Liippo,
E. Tala, and M. K. Viljanen.
1992.
Detection and identification of mycobacteria by amplification of a segment of the gene coding for the 32-kilodalton protein.
J. Clin. Microbiol.
30:2025-2028[Abstract/Free Full Text].
|
| 25.
|
Wilson, S. M.,
R. McNerney,
P. M. Nye,
P. D. Godfrey-Faussett,
N. G. Stoker, and A. Voller.
1993.
Progress toward a simplified polymerase chain reaction and its application to diagnosis of tuberculosis.
J. Clin. Microbiol.
31:776-782[Abstract/Free Full Text].
|
| 26.
|
Yuen, K. Y.,
K. S. Chan,
C. M. Chan,
B. S. W. Ho,
L. K. Dai,
P. Y. Chau, and M. H. Ng.
1993.
Use of PCR in routine diagnosis of treated and untreated pulmonary tuberculosis.
J. Clin. Pathol.
46:318-322[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, March 1998, p. 764-767, Vol. 36, No. 3
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Piersimoni, C., Scarparo, C.
(2003). Relevance of Commercial Amplification Methods for Direct Detection of Mycobacterium tuberculosis Complex in Clinical Samples. J. Clin. Microbiol.
41: 5355-5365
[Full Text]
-
Lumb, R., Davies, K., Dawson, D., Gibb, R., Gottlieb, T., Kershaw, C., Kociuba, K., Nimmo, G., Sangster, N., Worthington, M., Bastian, I.
(1999). Multicenter Evaluation of the Abbott LCx Mycobacterium tuberculosis Ligase Chain Reaction Assay. J. Clin. Microbiol.
37: 3102-3107
[Abstract]
[Full Text]